To make the phospho-PAK4/PAK5/PAK6 (S474/S560/S602) recombinant monoclonal antibody, the first step is to isolate the genes coding for the phospho-PAK4/PAK5/PAK6 (S474/S560/S602) antibody from the rabbits immunized with a synthesized peptide derived from human phospho-PAK4/PAK5/PAK6 (S474/S560/S602) protein. Secondly, these antibody genes are cloned into expression vectors. Thirdly, the modified vectors are transfected into host suspension cells. Fourthly, positive cells are cultured to express and secrete antibodies. The phospho-PAK4/PAK5/PAK6 (S474/S560/S602) recombinant monoclonal antibody is purified from the cell culture supernatant through affinity chromatography. Finally, the activity of the antibody is tested in ELISA, WB, and IF tests. This antibody can react with human phospho-PAK4/PAK5/PAK6 (S474/S560/S602) protein.

The ALPG recombinant monoclonal antibody was generated through the insertion of ALPG antibody genes into plasmid vectors, followed by transfection into appropriate host cells for exogenous protein expression. Subsequently, this recombinant monoclonal antibody underwent purification using affinity chromatography and validation for ELISA. In functional ELISA assays, it was observed that the ALPG recombinant monoclonal antibody could effectively bind to the human ALPG protein (CSB-MP001633HU) at a concentration of 2 μg/mL, demonstrating an EC₅₀ range of 14.09-23.17 ng/mL.

CUSABIO cloned PTK2 antibody-coding genes into plasma vectors and then transfected these vector clones into mammalian cells using a lipid-based transfection reagent. Following transient expression, the recombinant antibodies against PTK2 were harvested and characterized. The recombinant PTK2 antibody was purified by affinity-chromatography from the culture medium. It can be used to detect PTK2 protein from Human in the ELISA, WB.

PTK2 encodes a cytoplasmic protein tyrosine kinase that was found to be concentrated in focal adhesions formed between cells with components of the extracellular matrix. Diseases associated with PTK2 include malignant astrocytoma and ovarian cancer. Its related pathways include the NF-kappaB pathway and cytokine signaling in the immune system. According to some studies, PTK2 may have the following features.
PTK2 promotes the cancer stem cell signature of hepatocellular carcinoma by activating Wnt/β-catenin signaling. MiR-520d-5p inhibits CC cell proliferation, invasion and migration by targeting PTK2. PTK2 and EIF3S3 genes may be amplified targets of 8q23-q24 and are associated with large hepatocellular carcinoma. Moving and resting actin filaments are involved in the spreading of PtK2 cells after mitosis.

The generation of the CLDN4 recombinant monoclonal antibody involved the integration of CLDN4 antibody genes into plasmid vectors. These engineered plasmid vectors were subsequently introduced into appropriate host cells using exogenous protein expression techniques to facilitate antibody production. Following this production phase, the CLDN4 recombinant monoclonal antibody underwent purification through affinity chromatography. Comprehensive validation was conducted to confirm the suitability of this CLDN4 recombinant monoclonal antibody for both ELISA and FC applications.

CLDN4 protein is a critical component of tight junctions in epithelial tissues. Its main function is to establish and maintain the integrity of epithelial barriers, regulate ion and molecule transport across these barriers, and contribute to cell polarity and differentiation. Proper CLDN4 function is essential for the normal physiological function of various organs and tissues.